Adverse Event Reporting and Management

Reporting Bias in Severity Ratings of Adverse Events

Posted on digi By digi

Accurate severity grading of adverse events (AEs) is critical for patient safety, regulatory compliance, and trial credibility. Yet, despite the availability of standardized tools like the Common Terminology Criteria for Adverse Events (CTCAE), severity ratings often suffer from reporting bias. This bias arises when investigators or sponsors consciously or unconsciously misclassify the intensity of an AE, either overstating or understating its seriousness. Regulatory agencies such as the FDA, EMA, and MHRA have repeatedly cited severity misclassification as a major inspection finding, emphasizing the need for consistent and unbiased severity reporting.
Click to read the full article.

Adverse Event Reporting and Management, Causality and Severity Assessments

Reconciliation of Investigator and Sponsor Views on AE Causality

Posted on digi By digi

In clinical trials, both investigators and sponsors are required to assess whether an adverse event (AE) is related to the investigational product (IP). Investigators provide frontline, patient-level judgments, while sponsors apply a global perspective based on aggregate data and pharmacological knowledge. These dual perspectives are essential, but they often result in discrepancies. Regulators such as the FDA, EMA, and MHRA expect sponsors to reconcile these differences transparently and document them consistently in case report forms (CRFs), safety databases, and regulatory submissions.
Click to read the full article.

Adverse Event Reporting and Management, Causality and Severity Assessments

Documenting Rationale for Causality in Clinical Trials

Posted on digi By digi

Determining whether an adverse event (AE) is related to an investigational product (IP) is a cornerstone of clinical trial safety assessment. Equally important is the documentation of the rationale behind that decision. Regulatory authorities including the FDA, EMA, and MHRA require not just a classification of causality—such as “Unlikely,” “Possible,” or “Probable”—but also a justification that explains how the decision was reached. Without proper rationale, causality judgments may be seen as arbitrary, undermining both patient safety and regulatory compliance.
Click to read the full article.

Adverse Event Reporting and Management, Causality and Severity Assessments

What is a SUSAR and When to Report It?

Posted on digi By digi

In global clinical research, adverse event (AE) reporting is central to ensuring participant safety and regulatory compliance. Among the categories of AEs, one of the most critical is the Suspected Unexpected Serious Adverse Reaction (SUSAR). Regulatory authorities such as the FDA, EMA, MHRA, and global ICH guidelines require sponsors and investigators to identify and report SUSARs within strict timelines. Mismanagement of SUSAR reporting can result in delayed safety communication, missed signals, regulatory penalties, and even trial suspension.
Click to read the full article.

Adverse Event Reporting and Management, Regulatory Reporting Requirements (CIOMS, SUSARs)

CIOMS Form Completion Guidelines

Posted on digi By digi

The CIOMS (Council for International Organizations of Medical Sciences) form is a globally accepted standard for reporting Serious Adverse Events (SAEs) and Suspected Unexpected Serious Adverse Reactions (SUSARs) in clinical trials. While some regions also accept country-specific formats (e.g., FDA MedWatch Form 3500A), the CIOMS form is widely used in multinational trials to harmonize reporting. Regulatory authorities such as the EMA, MHRA, and PMDA recognize the CIOMS form as an acceptable format for expedited reporting.
Click to read the full article.

Adverse Event Reporting and Management, Regulatory Reporting Requirements (CIOMS, SUSARs)

SUSAR Reporting to Ethics Committees

Posted on digi By digi

Suspected Unexpected Serious Adverse Reactions (SUSARs) are among the most important safety signals in clinical trials. While regulators such as the FDA, EMA, and MHRA require expedited reporting, ethics committees (ECs)—also called Institutional Review Boards (IRBs)—play an equally critical role. Ethics committees are tasked with protecting trial participants, and timely access to SUSAR data enables them to assess whether ongoing participation remains ethically justifiable.
Click to read the full article.

Adverse Event Reporting and Management, Regulatory Reporting Requirements (CIOMS, SUSARs)

Global Variability in SUSAR Definitions

Posted on digi By digi

Suspected Unexpected Serious Adverse Reactions (SUSARs) are a cornerstone of pharmacovigilance in clinical trials. Yet, despite harmonization attempts under ICH E2A and CIOMS, definitions and interpretations of SUSARs vary significantly across regulatory regions. This variability creates complexity for sponsors conducting multinational trials, where a single adverse event may be classified differently depending on the jurisdiction. Misclassification or inconsistent reporting can result in inspection findings, delayed approvals, or regulatory sanctions.
Click to read the full article.

Adverse Event Reporting and Management, Regulatory Reporting Requirements (CIOMS, SUSARs)

Role of E2A and E2D Guidelines in Safety Reporting

Posted on digi By digi

In clinical trials, safety reporting is a global responsibility shared between sponsors, investigators, and regulators. To harmonize safety communication, the International Council for Harmonisation (ICH) developed the E2A and E2D guidelines, which define standards for expedited reporting and periodic safety updates. Together, these guidelines ensure that Suspected Unexpected Serious Adverse Reactions (SUSARs) are reported rapidly and that cumulative safety data is analyzed systematically.
Click to read the full article.

Adverse Event Reporting and Management, Regulatory Reporting Requirements (CIOMS, SUSARs)

Timeline Management for CIOMS Submission

Posted on digi By digi

In global clinical trials, CIOMS forms are the gold standard for documenting and reporting Serious Adverse Events (SAEs) and Suspected Unexpected Serious Adverse Reactions (SUSARs). Regulatory agencies such as the FDA, EMA, MHRA, and PMDA require expedited reporting within strict timelines, making time management a critical aspect of pharmacovigilance operations. Failure to comply with submission deadlines is among the most common causes of inspection findings, regulatory warnings, and trial delays.
Click to read the full article.

Adverse Event Reporting and Management, Regulatory Reporting Requirements (CIOMS, SUSARs)

Email vs Portal-Based CIOMS Submissions

Posted on digi By digi

The CIOMS form is an internationally recognized format for reporting Serious Adverse Events (SAEs) and Suspected Unexpected Serious Adverse Reactions (SUSARs). Over the years, submission methods have evolved from traditional fax and postal services to email-based submissions and, more recently, to secure regulatory portals. Each method has distinct advantages, limitations, and regulatory expectations. Choosing the right channel is not only an operational decision but also a matter of compliance and data integrity.
Click to read the full article.

Adverse Event Reporting and Management, Regulatory Reporting Requirements (CIOMS, SUSARs)